Oral vaccination against Helicobacter pylori with recombinant cholera toxin B-subunit
Oral vaccination against Helicobacter pylori with recombinant cholera toxin B-subunit
复制标题
DOI：
10.1111/j.1523-5378.2005.00328.x
复制
发表时间：
2005-08-01
期刊：
影响因子：
4.4
通讯作者：
Itoh, M
中科院分区：
文献类型：
--
作者：
Kubota, E;Joh, T;Itoh, M
背景。无毒的纯重组霍乱毒素B亚基（rCTB）作为宿主免疫的强佐剂非常有吸引力，但人们对rCTB针对幽门螺杆菌的胃粘膜免疫佐剂作用知之甚少。测试了rCTB对幽门螺杆菌的免疫佐剂作用。材料和方法。通过口服或鼻内超声处理的幽门螺杆菌和rCTB对小鼠进行免疫，并在免疫后第42天处死小鼠。进行被动皮肤过敏反应（PCA）测试，以评估来自已施用带有rCTB的幽门螺杆菌抗原的小鼠的血清的IgE介导的过敏反应。检查血清、胃肠道灌洗液和粪便中幽门螺杆菌特异性免疫球蛋白滴度。使用根据胃炎症分级定义的评分来评估攻击后接种疫苗的小鼠的胃炎。通过计数每克胃组织的菌落形成单位（CFU）来研究免疫后幽门螺杆菌的增殖。结果。 PCA测试显示，对用幽门螺杆菌抗原免疫并口服和鼻内施用rCTB的小鼠的血清没有反应。口服和鼻腔联合给予rCTB可显着提高针对幽门螺杆菌的全身和粘膜免疫力，并抑制胃粘膜中幽门螺杆菌的增殖。由于免疫后胃炎，口服免疫小鼠胃炎评分明显高于鼻腔免疫小鼠。与鼻内给药且不含rCTB相比，仅口服rCTB可抑制幽门螺杆菌增殖。结论。目前的研究表明，rCTB 对幽门螺杆菌具有全身和粘膜免疫佐剂作用，并且口服 rCTB 疫苗可能额外支持抗生素根除。
Background. The innocuous pure recombinant cholera toxin B-subunit (rCTB) is very attractive as a strong adjuvant for host immunization, but little is known about rCTB's gastric mucosal immunoadjuvanticity against Helicobacter pylori. The immunoadjuvanticity of rCTB against H. pylori was tested.Materials and methods. Mice were immunized with sonicated H. pylori and rCTB orally or intranasally and sacrificed on day 42 after immunization. Passive cutaneous anaphylaxis (PCA) test was performed to evaluate IgE-mediated anaphylaxis with serum from mice to which H. pylori-antigen with rCTB had been administered. Immunoglobulin titer specific to H. pylori in serum, lavation of the gastrointestinal tracts and feces were examined. Gastritis in vaccinated mice after a challenge was assessed with the scoring defined from grading of gastric inflammation. H. pylori proliferation after immunization was investigated by counting colony forming units (CFU) per gram of stomach tissue.Results. PCA test exhibited no reactions against the serum from mice immunized with H. pylori-antigen with rCTB administered orally and intranasally. Oral and nasal coadministrations of rCTB significantly raised systemic and mucosal immunities against H. pylori and suppressed proliferation of H. pylori in gastric mucosa. The score of gastritis in mice immunized orally was significantly higher than that of mice immunized nasally due to postimmunization gastritis. Only oral administration of rCTB suppressed H. pylori proliferation as compared with intranasal administration and without rCTB.Conclusions. The present study indicated that rCTB has systemic and mucosal immunoadjuvanticities against H. pylori and that oral vaccination with rCTB might additively support antibiotic eradication.